Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. - sprookjes - yvandenbroek - TriplyDB

Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion.

Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion.

http://www.wikidata.org/entity/Q34310143

about

Androgen deprivation-induced senescence promotes outgrowth of androgen-refractory prostate cancer cells Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra Androgen depletion induces senescence in prostate cancer cells through down-regulation of Skp2 Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer Evidence-based recommendations on androgen deprivation therapy for localized and advanced prostate cancer Fortifying the Treatment of Prostate Cancer with Physical Activity Mechanisms of resistance in castration-resistant prostate cancer (CRPC)Targeting molecular resistance in castration-resistant prostate cancer Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies Androgen receptor on the move: boarding the microtubule expressway to the nucleus Targeting the androgen receptor with steroid conjugates Peptidomimetic targeting of critical androgen receptor-coregulator interactions in prostate cancer Induction of paclitaxel resistance by ERα mediated prohibitin mitochondrial-nuclear shuttling Salvage radiotherapy after radical prostatectomy: prediction of biochemical outcomes Potential Cross-Talk between Alternative and Classical NF-κB Pathways in Prostate Cancer Tissues as Measured by a Multi-Staining Immunofluorescence Co-Localization Assay Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance 20(S)-protopanaxadiol-aglycone downregulation of the full-length and splice variants of androgen receptor.AR variant ARv567es induces carcinogenesis in a novel transgenic mouse model of prostate cancer.[Bone-specific therapy with radium-223 dichloride : Castration-resistant prostate cancer with symptomatic bone metastases].Androgen receptor splice variants and prostate cancer: From bench to bedside.Estradiol suppresses tissue androgens and prostate cancer growth in castration resistant prostate cancer.Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer.SUMO-Specific Cysteine Protease 1 Promotes Epithelial Mesenchymal Transition of Prostate Cancer Cells via Regulating SMAD4 deSUMOylation.Estrogen receptor α in cancer-associated fibroblasts suppresses prostate cancer invasion via modulation of thrombospondin 2 and matrix metalloproteinase 3 Withania somnifera targets interleukin-8 and cyclooxygenase-2 in human prostate cancer progression.Targeting drug-metabolizing enzymes for effective chemoprevention and chemotherapy.Interleukin-17 promotes development of castration-resistant prostate cancer potentially through creating an immunotolerant and pro-angiogenic tumor microenvironment.Inhibition of androgen receptor promotes CXC-chemokine receptor 7-mediated prostate cancer cell survival.The role of GATA2 in lethal prostate cancer aggressiveness.No increased risk of dementia in patients receiving androgen deprivation therapy for prostate cancer: a 5-year follow-up study.Telomerase as an important target of androgen signaling blockade for prostate cancer treatment.Rapid phenotypic and genomic change in response to therapeutic pressure in prostate cancer inferred by high content analysis of single circulating tumor cells Targeted BikDD expression kills androgen-dependent and castration-resistant prostate cancer cells.Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer Self-renewing Pten-/- TP53-/- protospheres produce metastatic adenocarcinoma cell lines with multipotent progenitor activity.Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors Upregulation of glucose metabolism by NF-κB2/p52 mediates enzalutamide resistance in castration-resistant prostate cancer cells.Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer PARP-1 regulates epithelial-mesenchymal transition (EMT) in prostate tumorigenesis

P2860

Q21132994-377A909F-7C72-497B-943B-074C40DD28A6 Q24289204-EFEC3658-4248-43E8-836D-3711A5762E1E Q24614665-ABBE3E54-575E-4BBC-B873-83ADBFC37B17 Q26739708-954172EA-4576-4883-8771-C8AEEB96E497 Q26739738-16266EFA-3E20-41FE-8449-827E87BB6791 Q26765503-AF4FA122-0A72-4BE2-BC6C-E8263EC738F4 Q26774221-9A31E3FD-2D9D-40F0-84AF-E79437E54B36 Q26795445-5E75F39C-6582-44F9-94B6-95F7CE21C7E6 Q26795625-B4CFEE29-5FA8-40A7-BDB4-7776EF147073 Q26796704-35A19F63-C29C-4C96-B21E-7A8242D11EE3 Q26862560-9419554A-9F90-40E4-B363-DD0B31647804 Q26995692-47D93B03-D508-41CE-B5A9-416B4E980CA9 Q28291526-DFEA1D76-C294-43DD-93F3-1EF1E7539D6F Q28537899-261FD39B-5676-4DAF-982D-6D0218D69C86 Q28541306-0B6D33EF-58CA-43A4-BEE4-27DE8590395B Q28546630-D00AF779-C528-48F4-BA87-A41DFA6ABD71 Q30500080-F790BA92-E45F-42C7-8C56-CDF7DD881C21 Q30528764-E49F523D-54A4-4691-8E9B-70D6AA3DF270 Q30544584-A2D1C648-FD15-46F5-9297-303F2D2D5387 Q33438196-86D8E3D6-480B-4B43-AFD6-B1A5480717E4 Q33567024-D0CB6D19-C657-4363-8DEC-7FD26EAA1622 Q33590201-929423BB-AB81-411E-810F-CF76826D9D28 Q33621403-FC304381-F695-4C4C-B4B5-2B247847E45A Q33624675-477BD8B4-B992-4EF8-B3F7-E45D3A081AE3 Q33705239-95233B51-601C-4578-86D0-22A4110F5B28 Q33739134-162ED2F0-9B67-4BFE-84C8-63CEFF1162AF Q33754817-1FD86608-ABF5-42D2-9E6D-35209B61D892 Q33777002-B3393FD5-6172-4A6E-9F8D-B4B970AC594C Q33780482-3B945912-48F7-4974-9CDC-857420196AEE Q33848134-7027B411-7AA8-4436-82ED-974FB7614695 Q33897252-D3E0708C-E45A-4038-85E5-097546C01B15 Q33981807-F189CF34-7CC4-4D86-B1D9-05FEAF2E8BC7 Q33988851-5DD03C3A-F4C9-40BE-8A3D-97106D50482F Q33998169-091A87CD-14C9-4D7F-B280-2EFECEBB53EB Q34028361-D32CCCBC-2F0F-43FD-9DCC-5DBF4C61E59E Q34056013-ED9CF4C9-D4D7-4AFA-8E3D-F04C19216F0C Q34141720-0B37AD30-D30D-46EF-9D68-31D4FCB53ED2 Q34411599-F7DEE278-6737-416A-B29C-BCB160BA9C4D Q34416771-AD58D370-DDC6-4695-AB71-D2E0D6BEF121 Q34434937-D0F9675C-55DD-4289-8FF6-D34D320E2B99

P2860

Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion.

http://www.wikidata.org/entity/Q34310143

description

2009 nî lūn-bûn

@nan

2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Androgen deprivation therapy: ...... optimizing androgen depletion.

@ast

Androgen deprivation therapy: ...... optimizing androgen depletion.

@en

Androgen deprivation therapy: ...... optimizing androgen depletion.

@nl

type

label

Androgen deprivation therapy: ...... optimizing androgen depletion.

@ast

Androgen deprivation therapy: ...... optimizing androgen depletion.

@en

Androgen deprivation therapy: ...... optimizing androgen depletion.

@nl

prefLabel

Androgen deprivation therapy: ...... optimizing androgen depletion.

@ast

Androgen deprivation therapy: ...... optimizing androgen depletion.

@en

Androgen deprivation therapy: ...... optimizing androgen depletion.

@nl

P1433

Q34310143-D4CD9E88-B4A8-44DE-9606-C1D99CD71ACE

P1476

Q34310143-278489E3-41A6-4A7C-9938-61CF7BD61D9C

P2093

Q34310143-5B5E018F-F7C1-4034-A9AF-BA1C0A4D52CB

Q34310143-979035F8-9F79-40A3-A386-AA6129A7FB1D

Q34310143-CE6E46E0-877C-438E-BD81-B958F72FBD83

Q34310143-DDE8AA90-D7AF-4DF9-9651-C76CD07832AE

P2860

Q34310143-02097785-8C3F-4DA1-90C9-03B3252B7426

Q34310143-0552C340-6FB6-4DCD-8AA5-C04C390158F6

Q34310143-085792EF-8567-4BFE-844E-990D7F16D46B

Q34310143-216732FC-945A-4B59-AFC0-DA4F7873D71B

Q34310143-23832C7E-9D49-4B46-A458-45EA4EAEECCD

Q34310143-32FD5AF4-8C97-49C8-83FD-54AE363EBDBC

Q34310143-36483CB2-4ECB-4473-9B89-ABACA89F64D0

Q34310143-3BADD74A-88CE-47D6-8463-B17818CCAAFD

Q34310143-3CA80C21-8EE2-456C-9B07-510F14BCDC10

Q34310143-40EB8629-C627-4A71-B12D-706AC4FAE5BD

P2888

Q34310143-EC21F12B-4B34-4BEE-AD2E-206F51D0CCA8

P304

Q34310143-DE7F4CF4-F9BB-4B12-81E1-06D349C947D6

P31

Q34310143-9D91DBB4-D66A-4AA7-A706-77EF29412544

P356

Q34310143-054C9CC2-FA06-44BE-B9C2-4E0F0AD6D0EA

P407

Q34310143-E3A447AC-14BA-4FAC-965E-706967537B06

P433

Q34310143-D8047B0F-3169-45A1-BB1D-2C44AEAE44A4

P478

Q34310143-1CDBCD8A-156A-4BB9-983D-332474E6ACDD

P577

Q34310143-9EFA80C0-DD66-44B5-9319-0B193DC9C42E

P5875

Q34310143-EBE4827F-D399-467B-BF27-91EE36B00BCE

P6179

Q34310143-19BF139F-6569-4B46-B2F3-90AC9D170980

P698

Q34310143-D564DE31-2EF0-49D6-B262-355654A9955B

P932

Q34310143-A992D5F0-66F9-44E4-B9BA-CFB0DBBB50AA

P356

P1433

Nature Reviews Urology

P1476

Androgen deprivation therapy: ...... optimizing androgen depletion.

@en

P2093

Bruce Montgomery

http://www.w3.org/2001/XMLSchema#string

Elahe A Mostaghel

http://www.w3.org/2001/XMLSchema#string

Peter S Nelson

http://www.w3.org/2001/XMLSchema#string

William P Harris

http://www.w3.org/2001/XMLSchema#string

P2860

Receptor for activated C kinase 1 (RACK1) and Src regulate the tyrosine phosphorylation and function of the androgen receptor

Modulation of Androgen Receptor Activation Function 2 by Testosterone and Dihydrotestosterone

Cancer statistics, 2008

Molecular determinants of resistance to antiandrogen therapy

Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world

The development of androgen-independent prostate cancer

Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate.

Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.

Management of complications of prostate cancer treatment.

The role of diethylstilbestrol in the treatment of prostate cancer.

P2888

P304

76-85

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NCPURO1296

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2009-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23986122

http://www.w3.org/2001/XMLSchema#string

P6179

1031198336

http://www.w3.org/2001/XMLSchema#string

P698

19198621

http://www.w3.org/2001/XMLSchema#string

P932

2981403

http://www.w3.org/2001/XMLSchema#string